Breaking Finance News

Raymond James Financial, Inc. disclosed Viveve Medical Inc (NASDAQ:VIVE), hiking its price target to $10.00 earlier today

Reporting a potential upside of 0.44%, Raymond James Financial, Inc. upped the price target of Viveve Medical Inc (NASDAQ:VIVE) to $10.00

On 05/03/2017, Cowen and Company released a statement about Viveve Medical Inc (NASDAQ:VIVE) upped the target price from $0.00 to $11.00 that suggested an upside of 0.36%.

Having a price of $6.95, Viveve Medical Inc (NASDAQ:VIVE) traded -2.86% lower on the day. With the last stock price up -18.35% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the same period. VIVE has recorded a 50-day average of $5.48 and a two hundred day average of $6.65. Trade Volume was down over the average, with 166,980 shares of VIVE changing hands under the typical 182,566

Recent Performance Chart

Viveve Medical Inc (NASDAQ:VIVE)

Viveve Medical Inc has with a one year low of $3.75 and a one year high of $11.16 and has a market capitalization of $0.

A total of 3 equity analysts have released a ratings update on VIVE. zero analysts rating the company a strong buy, three analysts rating the company a buy, zero analysts rating the company a hold, zero analysts rating the company a underperform, and finally zero analysts rating the company a sell with a one year target of $14.43.

About Viveve Medical Inc (NASDAQ:VIVE)

Viveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *